[Heparan sulfate: efficacy and safety in patients with chronic venous insufficiency].
Fifty patients suffering from chronic venous disease were treated for 30 days with heparan sulphate 100 mg per os, b.i.d., or mesoglycan 50 mg per os, t.i.d., in a single blind random study. Both therapies led to a marked improvement in comparison to basal clinical values, but patients treated with heparan sulphate showed the greatest and most rapid regression of symptoms, associated with a significant improvement in plethysmographic index of capacitance and venous flow. Patients treated with heparan sulphate also showed an increased fibrinolytic activity and a reduced antithrombin III consumption, both of which were statistically significant.
Agrati
A M
AM
II Divisione di Medicina Generale Brera, Ospedale Niguarda Ca Granda, Milano.
De Bartolo
G
G
Palmieri
G
G
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012449:Safety; D016037:Single-Blind Method; D014689:Venous Insufficiency / Q000188:drug therapy*
D006025:Glycosaminoglycans; D006497:Heparan Sulfate; C040617:mesoglycan
Eparansolfato: efficacia e tollerabilità in pazienti affetti da insufficienza venosa cronica.